Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHKA | P35790 | 4/20 | 0.83 |
| ▸ | NR4A2 | P43354 | 3/20 | 0.50 |
| ▸ | SOS2 | Q07890 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 2/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | FERMT2 | Q96AC1 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | EGFR | P00533 | 2/20 | 0.44 |
| ▸ | CSF1R | P07333 | 2/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.43 |
| ▸ | CCR1 | P32246 | 1/20 | 0.43 |
| ▸ | PKM | P14618 | 1/20 | 0.43 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.43 |
| ▸ | CASP1 | P29466 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10062533 | 0.93 | CHKA (0.77) | CHKANR4A2SOS2LMNASMN1; SMN2 | |
| SCHEMBL13450995 | 0.91 | CHKA (0.75) | CHKANR4A2SOS2LMNASMN1; SMN2 | |
| SCHEMBL7498608 | 0.91 | CHKA (0.75) | CHKANR4A2SOS2LMNASMN1; SMN2 | |
| SCHEMBL11136934 | 0.91 | CHKA (1.00) | CHKANR4A2SOS2LMNASMN1; SMN2 | |
| SCHEMBL610392 | 0.84 | CHKA (0.69) | CHKALMNAMAPTCYP1A2EGFR | |
| SCHEMBL30522270 | 0.84 | CHKA (0.69) | CHKALMNAMAPTCYP1A2EGFR | |
| SCHEMBL30058586 | 0.83 | CHKA (0.68) | CHKANR4A2SOS2LMNASMN1; SMN2 | |
| SCHEMBL1706258 | 0.83 | CHKA (0.68) | CHKANR4A2SOS2LMNASMN1; SMN2 | |
| SCHEMBL21346926 | 0.80 | CHKA (0.70) | CHKANR4A2SOS2LMNASMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL10573768 | 0.79 | CHKA (0.62) | CHKANR4A2SOS2LMNASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7781458-B2 | Derivatives of pyridine and quinoline | CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS (ES) | 2010-08-24 | — | — | US | claimed |
| EP-1710236-B1 | DERIVATIVES OF PYRIDINE AND QUINOLINE | CONSEJO SUPERIOR INVESTIGACION (ES) | 2010-03-24 | — | — | EP | claimed |
| EP-2085386-A2 | Pyridinium and quinolinium derivatives as Choline kinase inhibitors | Consejo Superior De Investigaciones Científicas (ES) | 2009-08-05 | — | — | EP | claimed |
| US-20070185170-A1 | Derivatives of pyridine and quinoline | CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS (ES) | 2007-08-09 | — | — | US | claimed |
| EP-1710236-A1 | DERIVATIVES OF PYRIDINE AND QUINOLINE | CONSEJO SUPERIOR INVESTIGACIONES CIENTIFICAS (CSIC) (ES) | 2006-10-11 | — | — | EP | claimed |
| WO-2015185780-A1 | SYMMETRICAL POLAR INHIBITORS OF CHOLINE KINASE WITH ANTI-TUMOUR ACTIVITY | UNIVERSIDAD DE GRANADA (ES) | 2015-12-10 | — | — | WO | disclosed |
| US-20150297576-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER | TRASLATIONAL CANCER DRUGS PHARMA S L (ES) | 2015-10-22 | — | — | US | disclosed |
| US-20150297576-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER | TRASLATIONAL CANCER DRUGS PHARMA S L (ES) | 2015-10-22 | — | — | US | disclosed |
| US-20150098927-A1 | METHODS FOR TREATMENT AND DIAGNOSIS OF CANCER | TRASLATIONAL CANCER DRUGS PHARMA, S.L. (ES) | 2015-04-09 | — | — | US | disclosed |
| US-20150004252-A1 | METHOD FOR PREDICTING THE CLINICAL RESPONSE TO CHEMOTHERAPY IN A SUBJECT WITH CANCER | TRASLATIONAL CANCER DRUGS PHARMA, S.L (ES) | 2015-01-01 | — | — | US | disclosed |
| US-8586613-B2 | Pyridinium and quinolinium derivatives | UNIVERSIDAD DE GRANADA (ES) | 2013-11-19 | — | — | US | disclosed |
| US-20120040021-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER | TRASLATIONAL CANCER DRUGS PHARMA, S.L. (ES) | 2012-02-16 | — | — | US | disclosed |
| EP-1710236-B1 | DERIVATIVES OF PYRIDINE AND QUINOLINE | CONSEJO SUPERIOR INVESTIGACION (ES) | 2010-03-24 | — | — | EP | disclosed |
| EP-1710236-B1 | DERIVATIVES OF PYRIDINE AND QUINOLINE | CONSEJO SUPERIOR INVESTIGACION (ES) | 2010-03-24 | — | — | EP | disclosed |
| US-20100068302-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER | TRASLATIONAL CANCER DRUGS PHARMA, S.L. (ES) | 2010-03-18 | — | — | US | disclosed |
| EP-2085386-A2 | Pyridinium and quinolinium derivatives as Choline kinase inhibitors | Consejo Superior De Investigaciones Científicas (ES) | 2009-08-05 | — | — | EP | disclosed |
| EP-2085386-A2 | Pyridinium and quinolinium derivatives as Choline kinase inhibitors | Consejo Superior De Investigaciones Científicas (ES) | 2009-08-05 | — | — | EP | disclosed |
| US-20070185170-A1 | Derivatives of pyridine and quinoline | CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS (ES) | 2007-08-09 | — | — | US | disclosed |
| US-20070185170-A1 | Derivatives of pyridine and quinoline | CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS (ES) | 2007-08-09 | — | — | US | disclosed |
| EP-1710236-A1 | DERIVATIVES OF PYRIDINE AND QUINOLINE | CONSEJO SUPERIOR INVESTIGACIONES CIENTIFICAS (CSIC) (ES) | 2006-10-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150297576-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER | ASAH1, ACER2, ASAH2 | CHKA 4/4885NR4A2 4295/4885SOS2 3712/4885 |
| US-20070185170-A1 | Derivatives of pyridine and quinoline | CHKA, CHKB, PHOSPHO1 | CHKA 1/4885NR4A2 4407/4885SOS2 4063/4885 |
| US-20150098927-A1 | METHODS FOR TREATMENT AND DIAGNOSIS OF CANCER | CHKA, CHKB, CEPT1 | CHKA 1/4885NR4A2 3879/4885SOS2 3110/4885 |
| US-20100068302-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER | ASAH1, ACER2, ASAH2 | CHKA 4/4885NR4A2 4295/4885SOS2 3712/4885 |
| US-20150004252-A1 | METHOD FOR PREDICTING THE CLINICAL RESPONSE TO CHEMOTHERAPY IN A SUBJECT WITH CANCER | CHKA, CHKB, DCK | CHKA 1/4885NR4A2 4566/4885SOS2 4252/4885 |
| US-20120040021-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER | ASAH1, ACER2, ASAH2 | CHKA 4/4885NR4A2 4295/4885SOS2 3712/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.